MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


IN BRIEF: Braveheart’s Phasefocus investment aims push into the US

ALN

Braveheart Investment Group PLC - Barnsley, England-based investor in small- and medium-sized businesses - Provides update on Phasefocus Holdings Ltd, in which Braveheart has a 44% holding. Notes Phasefocus recently appointed Nexus Scientific, a specialist in cell analysis instrument sales, to represent Livecyte products in North America. Livecyte is an imaging and analysis system which uses a novel method for high fidelity quantitative imaging and microscopy. Explains Nexus will be running a series of customer workshops, conference attendances and seminars, to raise the profile and sales of Livecyte in the US. Further, notes two new Livecyte applications have been developed and are scheduled for launch before the end of 2023.

Current stock price: 12.90 pence, up 12% in London on Wednesday

12-month change: up 5.3%

Copyright 2023 Alliance News Ltd. All Rights Reserved.